FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Kramer Kelly A. 2. Issuer Name and Ticker or Trading Symbol GILEAD SCIENCES INC [ GILD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
333 LAKESIDE DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
5/6/2020
(Street)
FOSTER CITY, CA 94404
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit   (1) 5/6/2020    A     1936       (2)  (2) Common Stock  1936   (1) 8730  D   
Non-qualified Stock Option (Right to Buy)  $77.47  5/6/2020    A     7886       (3) 5/6/2030  Common Stock  7886  $0  7886  D   

Explanation of Responses:
(1)  Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
(2)  100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting.
(3)  25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kramer Kelly A.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404
X



Signatures
/s/ Amy Kim by Power of Attorney for Kelly A. Kramer 5/7/2020
**Signature of Reporting Person Date
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Gilead Sciences Charts.